0001785530-26-000012
SEC filingWerewolf Therapeutics reported narrower operating and net losses in Q1 FY2026 versus Q1 FY2025, reflecting deliberate cost discipline amid an active strategic review — including curtailed R&D spending and workforce reductions — aimed at conserving capital while evaluating alternatives to advance the platform.
The Company continues its strategic review process, which is actively shaping near-term financial execution. Management explicitly links recent cost reductions — including curtailment of research and development spending and a reduction in force — to the need to conserve capital resources while evaluating alternatives to advance the platform and pipeline. This dynamic underpins the improvement across key loss metrics and cash flow performance.
Operating income for Q1 FY2026 was $(13.3)M, an improvement of 26.2% compared to $(18.0)M in Q1 FY2025. Net income improved similarly, at $(13.5)M versus $(18.1)M, representing a 25.2% year-over-year improvement in the magnitude of loss. Diluted EPS loss narrowed to $(0.28) from $(0.40), a 30.0% improvement. These improvements are not attributed to revenue generation — the Company remains pre-revenue — but to intentional operational adjustments made in response to the strategic review.
While overall costs declined, certain expenses increased selectively. Professional services fees rose due to engagement of external legal counsel, consultants, and advisors to support the strategic review — a targeted, purpose-driven outlay acknowledged in management commentary. This increase was partially offset by reductions in other general and administrative expenses, also tied to cost reduction efforts leading up to and during the review. Interest expense increased due to higher non-cash interest related to amortization of debt issuance costs — a separate accounting effect unrelated to operational decisions.
Management emphasizes that the outcome of the strategic review will inform future development plans and associated costs. There is no forward-looking guidance on timing or nature of potential outcomes; however, the Company reiterates its expectation that R&D costs will decrease in the near future as strategic alternatives are explored. This outlook reinforces the cause-and-effect relationship between the current review and the observed financial trends — positioning cost discipline not as a temporary adjustment, but as a direct response to an ongoing, company-defining process.